High-dose interleukin-2 therapy related adverse events and implications on imaging
High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to increase tumoricidal activity of the innate im...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2021-09-01
|
| Series: | Diagnostic and Interventional Radiology |
| Online Access: |
http://www.dirjournal.org/archives/archive-detail/article-preview/high-dose-interleukin-2-therapy-related-adverse-ev/54057
|
| _version_ | 1797691389413163008 |
|---|---|
| author | Neal R. Shah Brandon Declouette Kianoush Ansari-Gilani Mohammad S. Alhomoud Christopher Hoimes Nikhil H. Ramaiya Ezgi Güler |
| author_facet | Neal R. Shah Brandon Declouette Kianoush Ansari-Gilani Mohammad S. Alhomoud Christopher Hoimes Nikhil H. Ramaiya Ezgi Güler |
| author_sort | Neal R. Shah |
| collection | DOAJ |
| description | High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to increase tumoricidal activity of the innate immune system. HDIL-2 therapy is associated with a wide spectrum of immune-related adverse events (irAEs) that can be radiologically identified. HDIL-2 toxicity can manifest in multiple organ systems, most significantly leading to cardiovascular, abdominal, endocrine, and neurological adverse events. The collective impact of the irAEs and the rise of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors led to the demise of HDIL-2 as a primary therapy for mRCC and metastatic melanoma. However, with innovation in ICIs and the creation of mutant IL-2 conjugates, there has been a drive for combination therapy. Knowledge of the HDIL-2 therapy and HDIL-2 related adverse events with radiology relevance is critical in diagnostic image interpretation. |
| first_indexed | 2024-03-12T02:12:36Z |
| format | Article |
| id | doaj.art-dd941d07be5d4e49a0af082a3a613ac4 |
| institution | Directory Open Access Journal |
| issn | 1305-3825 1305-3612 |
| language | English |
| last_indexed | 2024-03-12T02:12:36Z |
| publishDate | 2021-09-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Diagnostic and Interventional Radiology |
| spelling | doaj.art-dd941d07be5d4e49a0af082a3a613ac42023-09-06T12:18:30ZengGalenos Publishing HouseDiagnostic and Interventional Radiology1305-38251305-36122021-09-0127568468910.5152/dir.2021.2050313049054High-dose interleukin-2 therapy related adverse events and implications on imagingNeal R. Shah0Brandon Declouette1Kianoush Ansari-Gilani2Mohammad S. Alhomoud3Christopher Hoimes4Nikhil H. Ramaiya5Ezgi Güler6 Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA Department of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, USA Department of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, USA Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to increase tumoricidal activity of the innate immune system. HDIL-2 therapy is associated with a wide spectrum of immune-related adverse events (irAEs) that can be radiologically identified. HDIL-2 toxicity can manifest in multiple organ systems, most significantly leading to cardiovascular, abdominal, endocrine, and neurological adverse events. The collective impact of the irAEs and the rise of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors led to the demise of HDIL-2 as a primary therapy for mRCC and metastatic melanoma. However, with innovation in ICIs and the creation of mutant IL-2 conjugates, there has been a drive for combination therapy. Knowledge of the HDIL-2 therapy and HDIL-2 related adverse events with radiology relevance is critical in diagnostic image interpretation. http://www.dirjournal.org/archives/archive-detail/article-preview/high-dose-interleukin-2-therapy-related-adverse-ev/54057 |
| spellingShingle | Neal R. Shah Brandon Declouette Kianoush Ansari-Gilani Mohammad S. Alhomoud Christopher Hoimes Nikhil H. Ramaiya Ezgi Güler High-dose interleukin-2 therapy related adverse events and implications on imaging Diagnostic and Interventional Radiology |
| title | High-dose interleukin-2 therapy related adverse events and implications on imaging |
| title_full | High-dose interleukin-2 therapy related adverse events and implications on imaging |
| title_fullStr | High-dose interleukin-2 therapy related adverse events and implications on imaging |
| title_full_unstemmed | High-dose interleukin-2 therapy related adverse events and implications on imaging |
| title_short | High-dose interleukin-2 therapy related adverse events and implications on imaging |
| title_sort | high dose interleukin 2 therapy related adverse events and implications on imaging |
| url |
http://www.dirjournal.org/archives/archive-detail/article-preview/high-dose-interleukin-2-therapy-related-adverse-ev/54057
|
| work_keys_str_mv | AT nealrshah highdoseinterleukin2therapyrelatedadverseeventsandimplicationsonimaging AT brandondeclouette highdoseinterleukin2therapyrelatedadverseeventsandimplicationsonimaging AT kianoushansarigilani highdoseinterleukin2therapyrelatedadverseeventsandimplicationsonimaging AT mohammadsalhomoud highdoseinterleukin2therapyrelatedadverseeventsandimplicationsonimaging AT christopherhoimes highdoseinterleukin2therapyrelatedadverseeventsandimplicationsonimaging AT nikhilhramaiya highdoseinterleukin2therapyrelatedadverseeventsandimplicationsonimaging AT ezgiguler highdoseinterleukin2therapyrelatedadverseeventsandimplicationsonimaging |